Description

Boston Scientific in MedSurg: Will Double-Digit Growth Silence Competitors?

Boston Scientific Corporation delivered robust financial results in the second quarter of 2025, exceeding both market expectations and its own guidance. The company reported operational sales growth of 22% and organic sales growth of 17%, surpassing its forecasted range of 13% to 15%. Adjusted earnings per share (EPS) increased by 23% to $0.75, also exceeding expectations. The company’s adjusted operating margin improved to 27.6%.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!